Ehsanollah Esfandiari

916 total citations · 2 hit papers
23 papers, 669 citations indexed

About

Ehsanollah Esfandiari is a scholar working on Dermatology, Rheumatology and Immunology and Allergy. According to data from OpenAlex, Ehsanollah Esfandiari has authored 23 papers receiving a total of 669 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Dermatology, 8 papers in Rheumatology and 7 papers in Immunology and Allergy. Recurrent topics in Ehsanollah Esfandiari's work include Dermatology and Skin Diseases (12 papers), Allergic Rhinitis and Sensitization (6 papers) and Asthma and respiratory diseases (5 papers). Ehsanollah Esfandiari is often cited by papers focused on Dermatology and Skin Diseases (12 papers), Allergic Rhinitis and Sensitization (6 papers) and Asthma and respiratory diseases (5 papers). Ehsanollah Esfandiari collaborates with scholars based in United States, Japan and United Kingdom. Ehsanollah Esfandiari's co-authors include Iain B. McInnes, Kenji Kabashima, Emma Guttman‐Yassky, Moreica Pabbruwe, John F. Tarlton, Anthony P. Hollander, Wael Kafienah, Xiaoqing Wei, Max Field and George B.M. Lindop and has published in prestigious journals such as The Lancet, The Journal of Immunology and Biomaterials.

In The Last Decade

Ehsanollah Esfandiari

22 papers receiving 661 citations

Hit Papers

An anti-OX40 antibody to treat moderate-to-severe atopic ... 2022 2026 2023 2024 2022 2024 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
    2022 99 citations Emma Guttman‐Yassky, Eric L. Simpson et al. The Lancet profile →
  2. OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target
    2024 39 citations Michael Croft, Ehsanollah Esfandiari et al. American Journal of Clinical Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ehsanollah Esfandiari United States 10 275 258 133 119 103 23 669
Shio Kobayashi Japan 13 394 1.4× 393 1.5× 94 0.7× 21 0.2× 144 1.4× 16 949
Arata Kikuchi Japan 15 133 0.5× 103 0.4× 270 2.0× 43 0.4× 121 1.2× 33 734
Enrique Montero Cuba 18 58 0.2× 423 1.6× 81 0.6× 25 0.2× 172 1.7× 51 879
B. Vitolo Italy 12 396 1.4× 281 1.1× 16 0.1× 29 0.2× 111 1.1× 20 727
Elena Gallo Italy 13 57 0.2× 191 0.7× 57 0.4× 39 0.3× 101 1.0× 23 648
G.J.M. Pruijn Netherlands 12 312 1.1× 227 0.9× 34 0.3× 28 0.2× 186 1.8× 13 634
Raffi Manoukian United States 12 111 0.4× 327 1.3× 40 0.3× 41 0.3× 260 2.5× 16 726
John P. Seery United Kingdom 12 126 0.5× 269 1.0× 71 0.5× 34 0.3× 215 2.1× 16 710
Barbara White Needleman United States 15 143 0.5× 414 1.6× 218 1.6× 50 0.4× 158 1.5× 24 934
Troy Noordenbos Netherlands 13 629 2.3× 591 2.3× 76 0.6× 33 0.3× 228 2.2× 21 1.0k

Countries citing papers authored by Ehsanollah Esfandiari

Since Specialization
Citations

This map shows the geographic impact of Ehsanollah Esfandiari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ehsanollah Esfandiari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ehsanollah Esfandiari more than expected).

Fields of papers citing papers by Ehsanollah Esfandiari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ehsanollah Esfandiari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ehsanollah Esfandiari. The network helps show where Ehsanollah Esfandiari may publish in the future.

Co-authorship network of co-authors of Ehsanollah Esfandiari

This figure shows the co-authorship network connecting the top 25 collaborators of Ehsanollah Esfandiari. A scholar is included among the top collaborators of Ehsanollah Esfandiari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ehsanollah Esfandiari. Ehsanollah Esfandiari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guttman‐Yassky, Emma, Eric L. Simpson, Ehsanollah Esfandiari, et al.. (2025). Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic Dermatitis. Dermatology and Therapy. 15(11). 3153–3171. 1 indexed citations
2.
Guttman‐Yassky, Emma, Eric L. Simpson, Robert Bissonnette, et al.. (2025). ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis. Immunotherapy. 17(2). 83–94. 5 indexed citations
3.
Croft, Michael, Ehsanollah Esfandiari, Hailing Hsu, et al.. (2024). OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target. American Journal of Clinical Dermatology. 25(3). 447–461. 39 indexed citations breakdown →
4.
Guttman‐Yassky, Emma, Ken Igawa, Kenji Kabashima, et al.. (2024). Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study. Dermatology and Therapy. 14(12). 3351–3366.
5.
Guttman‐Yassky, Emma, Eric L. Simpson, Kristian Reich, et al.. (2024). Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study. Advances in Therapy. 41(3). 928–931. 3 indexed citations
6.
Blauvelt, Andrew, Yang Zhao, Marci Clark, et al.. (2024). Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews. British Journal of Dermatology. 192(2). 247–260. 2 indexed citations
7.
8.
Guttman‐Yassky, Emma, Ehsanollah Esfandiari, Takahiro Arai, et al.. (2024). Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab. Archives of Dermatological Research. 316(10). 747–747. 3 indexed citations
9.
10.
Simpson, Eric L., et al.. (2023). 42942 Rocatinlimab demonstrates improvements in patient-reported outcomes in adult patients with moderate–severe atopic dermatitis in a Phase 2 trial. Journal of the American Academy of Dermatology. 89(3). AB83–AB83. 1 indexed citations
11.
Guttman‐Yassky, Emma, Eric L. Simpson, Kristian Reich, et al.. (2022). An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. The Lancet. 401(10372). 204–214. 99 indexed citations breakdown →
12.
Esfandiari, Ehsanollah, Mary Chen, Glennda Smithson, et al.. (2021). A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects. Clinical and Translational Science. 14(3). 820–828. 3 indexed citations
13.
Montero, Rosa, Athula Herath, Ehsanollah Esfandiari, et al.. (2018). Defining Phenotypes in Diabetic Nephropathy: a novel approach using a cross-sectional analysis of a single centre cohort. Scientific Reports. 8(1). 53–53. 9 indexed citations
14.
Huizinga, T., Anastas Batalov, Румен Стоилов, et al.. (2017). Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Research & Therapy. 19(1). 53–53. 30 indexed citations
15.
Guptill, Jeffrey T., Vern C. Juel, Janice M. Massey, et al.. (2016). Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 49(7). 472–479. 79 indexed citations
16.
17.
Huizinga, T., Anastas Batalov, Румен Стоилов, et al.. (2015). SAT0210 First-in-Patient Study of Namilumab, an Anti-GM-CSF Monoclonal Antibody, in Active Rheumatoid Arthritis: Results of the Priora Phase IB Study. Annals of the Rheumatic Diseases. 74. 733–733. 7 indexed citations
18.
Burmester, Gerd R, Michael E. Weinblatt, Iain B. McInnes, et al.. (2012). Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Annals of the Rheumatic Diseases. 72(9). 1445–1452. 132 indexed citations
19.
Pabbruwe, Moreica, Ehsanollah Esfandiari, Wael Kafienah, John F. Tarlton, & Anthony P. Hollander. (2009). Induction of cartilage integration by a chondrocyte/collagen-scaffold implant. Biomaterials. 30(26). 4277–4286. 76 indexed citations
20.
Esfandiari, Ehsanollah, Iain B. McInnes, George B.M. Lindop, et al.. (2001). A Proinflammatory Role of IL-18 in the Development of Spontaneous Autoimmune Disease. The Journal of Immunology. 167(9). 5338–5347. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shio Kobayashi Breakdown of academic impact, for papers by Arata Kikuchi Breakdown of academic impact, for papers by Enrique Montero Breakdown of academic impact, for papers by B. Vitolo Breakdown of academic impact, for papers by Elena Gallo Breakdown of academic impact, for papers by G.J.M. Pruijn Breakdown of academic impact, for papers by Raffi Manoukian Breakdown of academic impact, for papers by John P. Seery Breakdown of academic impact, for papers by Barbara White Needleman Breakdown of academic impact, for papers by Troy Noordenbos
Rankless by CCL
2026